valsartan has been researched along with cyclic gmp in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 6 (33.33) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Bohlender, J; Dietz, R; Haass, M; Höhnel, K; Luft, FC; Scheuermann, M; Thibault, G; Willenbrock, R | 1 |
| Carey, RM; de Gasparo, M; El-Kersh, M; Siragy, HM | 1 |
| Carey, RM; De Gasparo, M; El-Kersh, MA; Siragy, HM; Webb, RL | 1 |
| Abadir, PM; Carey, RM; Siragy, HM | 1 |
| Isaka, N; Ito, M; Kaibuchi, K; Kongo, M; Kureishi, Y; Moriki, N; Nakakuki, T; Nakano, T; Okamoto, R; Seko, T | 1 |
| Barker, TA; Berk, BC; Kennedy, AJ; Korshunov, VA; Massett, MP; Mohan, AM | 1 |
| Brown, NJ; Gebretsadik, T; LeFebvre, J; Murphey, LJ; Petro, JR; Shintani, A | 1 |
| Akimoto, T; Fujita, D; Hirata, Y; Kiyosue, A; Komuro, I; Morishita, Y; Myojo, M; Nagai, R; Nagata, D; Satonaka, H; Takahashi, M | 1 |
| Hasegawa, Y; Kim-Mitsuyama, S; Koibuchi, N; Kusaka, H; Lin, B; Nakagawa, T; Ogawa, H; Sueta, D | 1 |
| Ayalasomayajula, S; Greeley, M; Hsiao, HL; Kode, K; Langenickel, TH; Pal, P; Petruck, J; Prescott, MF; Rajman, I; Schuehly, U; Sunkara, G; Zhou, W | 1 |
| Chrysant, SG | 1 |
| Bianchi, F; Cotugno, M; Forte, M; Madonna, M; Marchitti, S; Rubattu, S; Stanzione, R; Volpe, M | 1 |
| Ayalasomayajula, S; Buchbjerg, J; Golor, G; Hinder, M; Langenickel, TH; Pal, P; Prescott, MF; Schuehly, U; Sunkara, G | 1 |
| Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH | 1 |
| Braunwald, E; DeVore, AD; Duffy, CI; Gurmu, Y; McCague, K; Morrow, DA; Prescott, MF; Rocha, R; Velazquez, EJ | 1 |
| Chaumais, MC; Cumont, A; Djessas, MRA; Gaignard, P; Guignabert, C; Hebert, G; Huertas, A; Humbert, M; Savale, L; Thuillet, R; Tu, L | 1 |
| Adams, V; Augstein, A; Barthel, P; Draskowski, R; Galli, R; Goto, K; Jannasch, A; Kirchhoff, V; Linke, A; Männel, A; Mittag, J; Schauer, A; Winzer, EB | 1 |
2 review(s) available for valsartan and cyclic gmp
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
Pharmacokinetic, pharmacodynamic, and antihypertensive effects of the neprilysin inhibitor LCZ-696: sacubitril/valsartan.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Clinical Trials as Topic; Cough; Cyclic GMP; Diuresis; Drug Combinations; Heart Failure; Heart Ventricles; Humans; Hypertension; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Stroke Volume; Tetrazoles; Valsartan; Vasodilation | 2017 |
4 trial(s) available for valsartan and cyclic gmp
| Article | Year |
|---|---|
Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Bradykinin; Bradykinin B2 Receptor Antagonists; Cross-Over Studies; Cyclic GMP; Diet, Sodium-Restricted; Female; Heart Rate; Humans; Hypertension; Male; Receptor, Bradykinin B2; Renin; Sodium; Tetrazoles; Valine; Valsartan | 2007 |
Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Cyclic GMP; Double-Blind Method; Drug Combinations; Drug Interactions; Humans; Hypertension; Male; Middle Aged; Sildenafil Citrate; Tetrazoles; Valsartan | 2018 |
Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects.
Topics: Administration, Oral; Adult; Aminobutyrates; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Cyclic GMP; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Drug Monitoring; Female; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Middle Aged; Nitroglycerin; Tetrazoles; Valsartan | 2018 |
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Cyclic GMP; Drug Combinations; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Tetrazoles; Treatment Outcome; Troponin; Valsartan | 2019 |
12 other study(ies) available for valsartan and cyclic gmp
| Article | Year |
|---|---|
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Diuresis; Heart Failure; Male; Myocardium; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Statistics, Nonparametric; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Cyclic GMP; Drug Synergism; Extracellular Space; Imidazoles; Kidney; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium; Tetrazoles; Valine; Valsartan | 2001 |
Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.
Topics: Administration, Oral; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cyclic GMP; Extracellular Space; Female; Imidazoles; Injections, Intravenous; Kidney; Losartan; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
Topics: Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cyclic GMP; Extracellular Space; Imidazoles; Kidney; Mice; Mice, Knockout; Nitrates; Nitric Oxide; Nitrites; Pyridines; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Receptors, Angiotensin; Receptors, Bradykinin; Sodium; Tetrazoles; Valine; Valsartan | 2003 |
RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta; Cells, Cultured; Cyclic AMP; Cyclic GMP; Hypertension; Muscle, Smooth, Vascular; Prazosin; Rats; Rats, Inbred SHR; Rats, Inbred WKY; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Stroke; Tetrazoles; Valine; Valsartan | 2004 |
Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
Topics: Amlodipine; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Carotid Artery, Common; Cyclic GMP; Male; Rats; Rats, Inbred BN; Receptor, Angiotensin, Type 2; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan | 2006 |
Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells.
Topics: AMP-Activated Protein Kinases; Animals; Antihypertensive Agents; Aorta; Benzimidazoles; Benzoates; Cyclic GMP; Enzyme Activation; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Signal Transduction; Telmisartan; Tetrazoles; Valine; Valsartan | 2014 |
LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Cardiomegaly; Circadian Rhythm; Cyclic GMP; Drug Combinations; Drug Evaluation, Preclinical; Endothelium, Vascular; Fibrosis; Heart; Hypertension; Inflammation; Male; Myocardium; Neprilysin; Oxidative Stress; Random Allocation; Rats, Inbred SHR; Sodium, Dietary; Tetrazoles; Valsartan; Vascular Remodeling | 2015 |
Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Cyclic GMP; Drug Combinations; Hypertension; Male; Neprilysin; Proteinuria; Rats; Rats, Inbred SHR; Stroke; Tetrazoles; Valsartan | 2018 |
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptides; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Valsartan | 2019 |
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Bosentan; Cell Proliferation; Cells, Cultured; Cyclic GMP; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Therapy, Combination; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Protease Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats, Wistar; Valsartan; Vascular Remodeling | 2021 |
Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Connectin; Cyclic GMP; Diastole; Disease Models, Animal; Drug Combinations; Electrocardiography; Female; Fibrosis; Glycated Hemoglobin; Heart Failure; Muscle, Skeletal; Muscular Atrophy; Natriuretic Peptide, Brain; Peptide Fragments; Phosphorylation; Rats, Mutant Strains; Valsartan; Ventricular Function, Left | 2021 |